Alumis Inc: Undisclosed Drug Program Halted, Phase 3 Terminated Alumis Inc. halted its undisclosed drug program. The drug was a potential Tepezza rival. Phase 3 development will not proceed. This discontinuation is a critical blow. Alumis Inc. has terminated its undisclosed drug program, previously positioned as a competitor to Amgen's Tepezza. The company will not advance the asset into planned Phase 3 development. This decision follows an internal assessment of the drug's prospects, though specific trial phase or endpoint metrics triggering the halt were not disclosed. The move signifies a complete cessation of development for this late-stage asset. This program halt, while not a direct regulatory rejection, preempts potential FDA or EMA review. Companies often discontinue programs based on internal data analysis, avoiding costly late-stage trials if efficacy or safety thresholds are not met. Procedurally, Alumis will likely update clinical trial registries (e.g., ClinicalTrials.gov) to reflect the program's termination. No specific 21 CFR reference applies directly to a voluntary program halt, but transparency rules encourage disclosure. The discontinuation removes a significant potential competitor for Amgen's Tepezza (teprotumumab) in the market. This benefits Amgen by reducing future competitive pressure. Other potential competitors, such as Viridian Therapeutics' VRDN-001, may now gain a stronger market position. Alumis is now forced to explore strategic alternatives. The company's next pipeline update is expected by Q4 2026.